Matt Miksic
Stock Analyst at Barclays
(3.78)
# 693
Out of 4,876 analysts
282
Total ratings
59.11%
Success rate
4.31%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $19 → $16 | $12.07 | +32.56% | 5 | Jun 9, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $261 → $241 | $169.97 | +41.79% | 1 | Jun 3, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $56 → $55 | $45.83 | +20.02% | 7 | May 8, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $16 → $12 | $2.98 | +302.68% | 2 | May 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $90 → $93 | $85.04 | +9.36% | 6 | May 5, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $234 → $266 | $309.83 | -14.15% | 8 | Apr 30, 2025 | |
| INMD InMode | Maintains: Overweight | $29 → $24 | $14.07 | +70.58% | 13 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $125 | $104.58 | +19.53% | 17 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $684 → $635 | $534.19 | +18.87% | 7 | Apr 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $166 → $165 | $152.01 | +8.55% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $133.67 | +18.95% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $30.50 | +34.43% | 21 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $53 | $19.11 | +177.34% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $58.82 | +75.11% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $90 | $77.15 | +16.66% | 28 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $91.74 | +22.08% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $390.40 | +13.47% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $10.90 | +92.66% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.00 | +450.00% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $86.18 | +26.48% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $8.98 | +78.17% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $87.11 | +10.21% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $73.19 | +36.63% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $187.74 | +122.65% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $11.36 | +146.48% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $16.00 | +318.75% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $7.74 | +6,101.55% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $12.21 | +612.53% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $3.61 | +592.52% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $5.94 | +51.52% | 1 | Dec 12, 2016 |
Bausch + Lomb
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $12.07
Upside: +32.56%
Becton, Dickinson and Company
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $169.97
Upside: +41.79%
LivaNova
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $55
Current: $45.83
Upside: +20.02%
Orchestra BioMed Holdings
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.98
Upside: +302.68%
DexCom
May 5, 2025
Maintains: Equal-Weight
Price Target: $90 → $93
Current: $85.04
Upside: +9.36%
Insulet
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $309.83
Upside: -14.15%
InMode
Apr 30, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $14.07
Upside: +70.58%
Boston Scientific
Apr 25, 2025
Maintains: Overweight
Price Target: $118 → $125
Current: $104.58
Upside: +19.53%
Intuitive Surgical
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $534.19
Upside: +18.87%
Johnson & Johnson
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $166 → $165
Current: $152.01
Upside: +8.55%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $133.67
Upside: +18.95%
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $30.50
Upside: +34.43%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $19.11
Upside: +177.34%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $58.82
Upside: +75.11%
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $77.15
Upside: +16.66%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $91.74
Upside: +22.08%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $390.40
Upside: +13.47%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.90
Upside: +92.66%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.00
Upside: +450.00%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $86.18
Upside: +26.48%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $8.98
Upside: +78.17%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $87.11
Upside: +10.21%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $73.19
Upside: +36.63%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $187.74
Upside: +122.65%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.36
Upside: +146.48%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $16.00
Upside: +318.75%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $7.74
Upside: +6,101.55%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $12.21
Upside: +612.53%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $3.61
Upside: +592.52%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $5.94
Upside: +51.52%